

**P&T Motion History  
Newer Anticoagulant Drugs**

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate	Reiteration of prior motion	Decision
apixaban dabigatran edoxaban rivaroxaban	<p>After considering the evidence of safety, efficacy and special populations for direct acting anticoagulant drugs for their FDA approved indications, I move that apixaban, dabigatran, edoxaban, and rivaroxaban are safe and efficacious for their approved indications. Apixaban, dabigatran, edoxaban, and rivaroxaban cannot be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Davydow 2<sup>nd</sup>: Barkett</p>	February 28, 2024	N/A	N/A	Passed unanimous
	<p>After considering the evidence of safety, efficacy and special populations for direct acting anticoagulant drugs for their FDA approved indications, I move that apixaban, dabigatran, edoxaban, and rivaroxaban are safe and efficacious for their approved indications. Apixaban, edoxaban and rivaroxaban can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Figueroa 2<sup>nd</sup>: Park</p>	June 20, 2018	Yes Figueroa Schwilke	No	Passed unanimous